Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Nov 1;55(2):334–342. doi: 10.1093/jrr/rrt127

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2013. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Therapeutic Radiology and Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 1. — Gd-enhanced T1-weighted MR images. (A) Cecal cancer brain metastases in a 43-year-old male. A pons tumor was treated with a marginal dose of 31 Gy in five fractions at a 51% isodose (left). A significant tumor response and no adverse imaging effects were found five months after the five-fraction CyberKnife radiotherapy (right). The right hemiparesis disappeared and the KPS improved from 60 to 70. (B) A lung cancer (non-small-cell) brain metastasis in a 78-year-old male. A tumor in the occipital lobe with perifocal edema was treated with a marginal dose of 31 Gy in five fractions at a 54% isodose (left). A tumor response was found eight months after five-fraction radiotherapy (right). (C) Lung cancer (non-small-cell) brain metastases in a 53-year-old male. A tumor in the visual area with perifocal edema was treated with a marginal dose of 29 Gy in five fractions at a 53% isodose, and a right thalamic tumor was treated with a marginal dose of 27 Gy in three fractions at a 54% isodose (left). A tumor response was found seven months after treatment. Both tumors decreased in size and no adverse effects were observed (right).